Pharma stocks: Lupin, a pharma sector giant Lupin, has received four objections from the American Drug Regulator, Food and Drug Administration (US FDA) for its Pune -based biotech plant. These objections came to light during the investigation conducted before approved a particular drug. Due to this news, Lupine shares can remain in focus on Monday 22 September.
Lupine said in an information sent to the stock markets, the product-specific pre-functional inspection took place between September 8 to September 19. Lupine has stated that it will respond to these observation within the stipulated time and is committed to meet the quality standards of the current Good Manufacturing Practice (CGMP) in all units.
Earlier, on September 18, Lupine also got a major relief from the US FDA. The company has received the approval of Lenalidomide Capsule (2.5 Mg to 25 Mg Range) under its Abbladed New Drug Application (Anda). This drug is considered important in cancer therapy and will strengthen the company’s generic portfolio.
The Mumbai headquarters Lupine is a global level pharma company, whose products are available in more than 100 countries of the world. The company’s portfolio extends to branded and generic formulations, complex generics, biotechnology products and active pharmaceutical ingredients (APIs).
Stock performance weakness
However, Lupine’s performance in the stock market has been weak this year. Lupine shares closed at Rs 2,057.00 on Friday, September 19, with a gain of 0.51 per cent on NSE. Its stock gained 1.27% in the last 5 business days, but in 2025 it has fallen by 13% so far. The Nifty 50 index has risen 6.66% in the same period. That is, the stockmark Nifty is underperforming more than 50 to 7% of the stockmark Nifty this year.
Disclaimer: The ideas and investment advice given by experts/brokerage firms on Moneycontrol are their own, not the website and its management. Moneycontrol advises users to consult a certified expert before making any investment decision.